ERAS

Erasca Inc. (ERAS) | Rumor.io

Erasca

ERAS

Attention (50-day avg)0%

Attention rank (50-day avg)#1,156

Bullish sentiment (50-day avg)94%

Price to earnings ratio-32.2

Market capitalization4.9B

Earnings per share-0.95

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-124.5M

Social

What share of all stock conversation is about ERAS?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% +0	0% +0

Jun 1

Erasca's (ERAS) stock price surged 16.4% after announcing an exclusive global licensing agreement for an advanced clinical-stage oncology asset.
The strategic pipeline expansion is seen as a positive for the company's targeted cancer therapy portfolio, renewing investor enthusiasm.
Institutions are loading up on ERAS, with some analysts suggesting its compound is more potent than that of rival RVMD, citing its potential for growth.

Generated by AI

Sentiment

Of the messages about ERAS that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	100%	92.2% -7.8	69.81% -16.76
Bearish	—	0%	7.8% +7.8	30.19% +16.76

Bullish· Apr 28

ERAS has seen significant price appreciation, with a 1000% increase in a single day and a 400% increase the following day.
ERAS' valuation has been increasing, with some investors pricing it for perfection and others considering it a buying opportunity due to its strong data and potential for rebound.
ERAS has a strong potential for growth, with some investors already experiencing significant profits and others anticipating a rebound, with one investor considering it a "best in class" opportunity.

Bearish· Apr 28

ERAS is experiencing a significant decline, with some investors suggesting it may be headed for bankruptcy due to patent infringement issues and a toxic drug.
The company's recent update on its pan-RAS phase 1 trial was not well-received, leading to a sharp drop in the stock price.
ERAS's stock price has fallen by over 30% premarket, and some analysts believe it may take several months for the stock to recover from the current decline.

Generated by AI

Topics

Of the messages about ERAS that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	35.82%	73.11%	40.93%
Analysts	—	44.78%	14.15%	7.49%
Controversies	—	0%	6.6%	3.67%
Macro	—	19.4%	6.13%	37.76%
Technical Analysis	—	0%	0%	8.74%
Earnings	—	0%	0%	1.41%

Jan 8

Erasca's trial was placed on partial clinical hold due to safety concerns, which may delay the progress of its potential RAS inhibitor.
Erasca will present at the J.P. Morgan Healthcare Conference, increasing investor access and pushing speculative buying into the stock.
Erasca is developing potentially first-in-class and best-in-class RAS/KRAS inhibitors, such as ERAS-4001, for various solid tumors, with a multi-target approach to overcome drug resistance.

Generated by AI

Community

Of the messages about ERAS, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	45.39%	43.49%	36.02%
Newcomers	—	54.61%	56.51%	63.98%

Apr 28

The newcomer is concerned about the company's alleged theft of trade secrets from the US and is urging swift action to address the issue.
The newcomer points out a potential weakness in the $RVMD trial design, which excludes patients with a history of ILD or pneumonitis, contrasting with the $ERAS trial.
The newcomer questions the validity of the $ERAS trial data, citing differences in patient populations and treatment protocols compared to the $RVMD trial, and expresses skepticism about the company's reporting.

Generated by AI

On August 24, Erasca (NASDAQ:ERAS) announced that the FDA had granted Fast Track Designation to ERAS-0015, its oral pan-RAS molecular glue, for patients with metastatic pancreatic adenocarcinoma. The designation gives Erasca more frequent contact with regulators and, if the drug keeps clearing bars, a shot at accelerated approval, priority review, and rolling review. For a […]

25d agoYahoo Finance

Analysts Offer Insights on Healthcare Companies: Neurocrine (NBIX), Erasca (ERAS) and GlaxoSmithKline (GSK)

Detailed price information for Gsk Plc ADR (GSK-N) from The Globe and Mail including charting and trades.

1mo agoThe Globe and Mail

Erasca receives FDA fast track status for pancreatic cancer drug

1mo agoInvesting.com

Erasca Granted FDA Fast Track Designation for Pan-RAS Molecular Glue ERAS-0015 in Patients with Metastatic Pancreatic Adenocarcinoma

Designation follows encouraging Phase 1 activity across multiple tumor types including 2L+ KRAS G12X pancreatic cancer Three potentially...

1mo agoBarchart.com

Stifel reiterates Buy rating on Erasca stock, $30 target

1mo agoInvesting.com

Guggenheim raises Erasca stock price target to $21 on pipeline progress

1mo agoInvesting.com

Also Discussed

Investors talking about ERAS also mention

#	Name	Attention
1	Revolution Medicines, Inc.RVMD	0.01%-0.01
2	Adlai Nortye Group Ltd. American Depositary SharesANL	0%0
3	Zentalis Pharmaceuticals, Inc.ZNTL	0%new
4	Tango Therapeutics Inc.TNGX	0%new
5	Monte Rosa Therapeutics, Inc.GLUE	0%0
6	Immuneering Corp. Class A Common StockIMRX	0%0
7	Janux Therapeutics, Inc.JANX	0%0
8	Brand Engagement Network Inc.BNAI	0%+0
9	VTYX - Ventyx Biosciences, Inc.	——
10	TERN - Terns Pharmaceuticals, Inc.	——

Erasca Inc.

Healthcare
Biotechnology

Erasca Inc. is a clinical-stage precision oncology company focused on discovering, developing, and commercializing therapies for cancers driven by the RAS/MAPK signaling pathway. The company’s current portfolio centers on targeted drug candidates designed to address difficult-to-treat solid tumors through biomarker-guided approaches. Its development programs span multiple mechanisms, including agents that act on key nodes within the RAS/MAPK pathway and therapies intended to overcome resistance pathways in cancer cells. Erasca’s work is concentrated on precision medicine in oncology, with an emphasis on selecting patient populations most likely to benefit from its investigational treatments. Based in San Diego, California, Erasca plays a role in the biotechnology market as a research-driven company advancing experimental cancer therapies through clinical development and collaborative studies.

Website

Location

3115 Merryfield Row

San Diego, CA, 92121

United States

Social

What share of all stock conversation is about ERAS?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% +0	0% +0

Jun 1

Erasca's (ERAS) stock price surged 16.4% after announcing an exclusive global licensing agreement for an advanced clinical-stage oncology asset.
The strategic pipeline expansion is seen as a positive for the company's targeted cancer therapy portfolio, renewing investor enthusiasm.
Institutions are loading up on ERAS, with some analysts suggesting its compound is more potent than that of rival RVMD, citing its potential for growth.

Generated by AI

Sentiment

Of the messages about ERAS that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	100%	92.2% -7.8	69.81% -16.76
Bearish	—	0%	7.8% +7.8	30.19% +16.76

Bullish· Apr 28

ERAS has seen significant price appreciation, with a 1000% increase in a single day and a 400% increase the following day.
ERAS' valuation has been increasing, with some investors pricing it for perfection and others considering it a buying opportunity due to its strong data and potential for rebound.
ERAS has a strong potential for growth, with some investors already experiencing significant profits and others anticipating a rebound, with one investor considering it a "best in class" opportunity.

Bearish· Apr 28

ERAS is experiencing a significant decline, with some investors suggesting it may be headed for bankruptcy due to patent infringement issues and a toxic drug.
The company's recent update on its pan-RAS phase 1 trial was not well-received, leading to a sharp drop in the stock price.
ERAS's stock price has fallen by over 30% premarket, and some analysts believe it may take several months for the stock to recover from the current decline.

Generated by AI

Topics

Of the messages about ERAS that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	35.82%	73.11%	40.93%
Analysts	—	44.78%	14.15%	7.49%
Controversies	—	0%	6.6%	3.67%
Macro	—	19.4%	6.13%	37.76%
Technical Analysis	—	0%	0%	8.74%
Earnings	—	0%	0%	1.41%

Jan 8

Erasca's trial was placed on partial clinical hold due to safety concerns, which may delay the progress of its potential RAS inhibitor.
Erasca will present at the J.P. Morgan Healthcare Conference, increasing investor access and pushing speculative buying into the stock.
Erasca is developing potentially first-in-class and best-in-class RAS/KRAS inhibitors, such as ERAS-4001, for various solid tumors, with a multi-target approach to overcome drug resistance.

Generated by AI

Community

Of the messages about ERAS, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	45.39%	43.49%	36.02%
Newcomers	—	54.61%	56.51%	63.98%

Apr 28

The newcomer is concerned about the company's alleged theft of trade secrets from the US and is urging swift action to address the issue.
The newcomer points out a potential weakness in the $RVMD trial design, which excludes patients with a history of ILD or pneumonitis, contrasting with the $ERAS trial.
The newcomer questions the validity of the $ERAS trial data, citing differences in patient populations and treatment protocols compared to the $RVMD trial, and expresses skepticism about the company's reporting.

Generated by AI

Erasca

Social

Jun 1

Sentiment

Bullish· Apr 28

Bearish· Apr 28

Topics

Jan 8

Community

Apr 28

News

FDA Fast Track Puts Erasca’s (ERAS) Pancreatic Bet Center Stage

Analysts Offer Insights on Healthcare Companies: Neurocrine (NBIX), Erasca (ERAS) and GlaxoSmithKline (GSK)

Erasca receives FDA fast track status for pancreatic cancer drug

Erasca Granted FDA Fast Track Designation for Pan-RAS Molecular Glue ERAS-0015 in Patients with Metastatic Pancreatic Adenocarcinoma

Stifel reiterates Buy rating on Erasca stock, $30 target

Guggenheim raises Erasca stock price target to $21 on pipeline progress

Also Discussed

Erasca Inc.

Company Information

Location

News

FDA Fast Track Puts Erasca’s (ERAS) Pancreatic Bet Center Stage

Analysts Offer Insights on Healthcare Companies: Neurocrine (NBIX), Erasca (ERAS) and GlaxoSmithKline (GSK)

Erasca receives FDA fast track status for pancreatic cancer drug

Erasca Granted FDA Fast Track Designation for Pan-RAS Molecular Glue ERAS-0015 in Patients with Metastatic Pancreatic Adenocarcinoma

Stifel reiterates Buy rating on Erasca stock, $30 target

Guggenheim raises Erasca stock price target to $21 on pipeline progress

Also Discussed

Social

Jun 1

Sentiment

Bullish· Apr 28

Bearish· Apr 28

Topics

Jan 8

Community

Apr 28